索拉非尼治疗肝细胞癌机制的研究进展

摘要

Sorafenib(Nexavar)is the only oral multi-kinase inhibitor which has been approved in the treatment of advanced hepatocellular carcinoma(HCC).With the development of its clinical applications,sorafenib's anti-cancer mechanisms have been more and more concerned.Sorafenib can not only act on the RAF/MEK/ERK pathway,shp 1/STAT3 pathway,Wnt/β-catenin pathway and endoplasmic reticulum pathway,but also affect the genes and enzymes, then inhibits proliferation and angiogenesis.This review provides an overview of the underlying mechanisms of sor-afenib in the treatment of HCC.%索拉非尼（多吉美，Sorafenib）是唯一被批准用于治疗晚期原发性肝细胞癌（hepatocellular carci-noma，HCC）的口服多激酶抑制剂。随着索拉非尼临床应用的发展，其抗癌机制被越来越多的人关注。索拉非尼不仅能作用于 RAF/MEK/ERK通路、shp 1/STAT3相关通路、Wnt/β-catenin通路和内质网途径，还能影响相关基因和酶类，从而达到抑制肿瘤细胞增殖和肿瘤新生血管生成的作用。本文就近年来索拉非尼治疗HCC 机制的研究进展作一综述。